| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
To our knowledge, there is no report that analyzed the various biomarkers of cerebrospinal fluid (CSF) that evaluate degree of damage to axon, astrocytes, and Schwann cells. Therefore, we determined levels of biomarkers reflecting damage to these cells in the CSF of patients with worsening symptoms of cervical compression myelopathy. We collected 69 samples of CSF from patients before spinal surgery for acutely worsening compression myelopathy (AM, 20), chronic compression myelopathy (CM, 20), and lumbar canal stenosis (LCS; control group 29). As the result, significantly higher levels of pNF-H and Tau that reflect axonal damage were detected in the CSF of patients with AM compared with those in either CM or LCS group. On the other hands, the level of MBP, S100b, and NSE were not significantly different between the three groups. The present results suggest that axonal damage is remarkable compared with demyelination, astrocytic, and neuronal damage in AM.
|
